SOLVApril 28, 2026 at 3:06 PM UTCHealth Care Equipment & Services

Solventum Earnings Preview: Growth Expectations Clash with DeepValue's SELL Thesis

Read source article

What happened

Solventum reports next week with Wall Street expecting earnings growth, but the latest DeepValue Master Report maintains a SELL rating, citing a DCF intrinsic value of $25.39 versus the current $73.88—a 191% overvaluation. Free cash flow has declined sharply from $1.93 billion in 2021 to $805 million in 2024, while leverage remains elevated at 4.75x net debt/EBITDA and interest coverage of 5.44x. Operating expenses have risen, and EPS has been volatile, with no identified moat or tailwinds to support the current valuation. The upcoming earnings report could provide a near-term catalyst if results beat expectations, but the structural bear case hinges on sustained cash flow weakness and balance sheet risk. Investors should watch for any improvement in FCF trends or debt reduction that could narrow the gap to intrinsic value, but absent such catalysts, the stock appears significantly overpriced.

Implication

While an earnings beat may lift the stock in the short term, the DeepValue report’s SELL rating is grounded in a DCF valuation of $25.39, 191% below the current price. Free cash flow has halved since 2021, leverage is high (net debt/EBITDA 4.75x), and no durable competitive advantage is identified. The upcoming earnings report will be a key catalyst: if results fall short, the stock could correct sharply. Conversely, even a strong quarter is unlikely to reverse the fundamental deterioration without sustained cash flow recovery and debt reduction. Investors should treat any earnings-driven rally as an opportunity to reduce exposure, not a reason to buy.

Thesis delta

The Zacks article paints an optimistic near-term picture, but the DeepValue report's fundamental analysis suggests the stock is structurally overvalued. The upcoming earnings report could provide a temporary positive catalyst, but the thesis remains bearish without proof of improving cash generation and deleveraging. No shift in stance; the SELL rating stands.

Confidence

Low